New pill targets skin disease in 12-Week trial
NCT ID NCT07234591
Summary
This study is testing a new oral medication called a TYK2 inhibitor for people with moderate to severe plaque psoriasis. About 140 participants will take either the real pill or a placebo (sugar pill) for 12 weeks to see if it safely reduces skin redness, thickness, and scaling. The main goal is to see how many people achieve a 75% improvement in their skin symptoms.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Skin Disease Hospital
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.